Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director
September 4, 2024Dr Paulo Fontoura brings 20 yearsโ experience of working in the pharma industry, with the most recent 16 years focusing…Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investorsโ Dementia Discovery Fund and Two Bear Capital to Develop Safer, More Effective Neuroscience Drugs Using a Novel Brain-Only Pharmacology Approach
August 2, 2024SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- Montara Therapeutics, Inc. (โMontaraโ), a therapeutics company aiming to revolutionize the discovery…Newly established SAB of prominent geneticists, biologists and Huntingtonโs disease specialistsโ marks pivotal step in accelerating progress of lead programme HRN001
May 30, 2024Newly established SAB of prominent geneticists, biologists and Huntingtonโs disease specialistsโ marks pivotal step in accelerating progress of lead programme…Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
May 23, 2024Cambridge, UK, May 23, 2024 โ Amphista Therapeutics (โAmphistaโ), a leader in next generation targeted protein degradation (TPD) approaches, today announces…Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy
May 21, 2024Designation Supports Accelerated Drug Development for PSP TPN-101 is the First PSP Treatment to Reduce NfL and IL-6 Levels, Key Biomarkers…Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
May 9, 2024Sacramento, May 8, 2024 (GLOBE NEWSWIRE) โ Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven…Cerevance Achieves First Milestone in Research Collaboration with Merck
May 2, 2024BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system…Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
April 25, 2024Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others…Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
April 24, 2024Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a…AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
April 15, 2024LONDON โ APRIL 15, 2024 โ AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines…Cumulus Neuroscience Announces First Patient Enrolled in AccelADx Electroencephalogram (EEG) Study for Early Detection of Alzheimer’s Dementia
March 14, 2024NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer's Dementia. Cumulus Neuroscience today announced the enrollment…Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinsonโs Disease Based on Nitration Discovery in Oral Presentation at the Alzheimerโs Disease and Parkinsonโs Disease (AD/PD) Conference
March 11, 2024-Nitraseโs first-in-class antibody found to significantly delay progression of Parkinsonโs disease in preclinical models by blocking the propagation of pathogenic…Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
February 13, 2024CARMEL, IN - Sudo Biosciences (โSudoโ), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors,…Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia
February 13, 2024TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP…Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
January 24, 2024Cambridge, UK, January 24th, 2024 โ Amphista Therapeutics (โthe Companyโ or โAmphistaโ), a leader in next generation targeted protein degradation (TPD)…Harness Therapeutics secures additional ยฃ4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
November 28, 2023Cambridge, UK, 28th November 2023: Harness Therapeutics (โHarnessโ, previously Transine Therapeutics), a biotechnology company focused on physiological protein upregulation to…Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck
November 21, 2023Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck This transaction highlights DDFโs attractive strategy of investing in…Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for theTreatment of Progressive Supranuclear Palsy to be Presented at the AD/PDโข 2024 International Conference on Alzheimerโs and Parkinsonโs Diseases
November 14, 202324-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a keybiomarker of neurodegeneration in tauopathies…AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
November 6, 2023โข AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain…Cumulus Neuroscience to Present Data at CTAD 2023 Annual Meeting
October 18, 2023BELFAST, Northern Ireland and CAMBRIDGE, Mass., October 18, 2023 / -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused…AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations
October 10, 2023โข AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a functional copy of the GRN…AstronauTx closes a ยฃ48 million ($61 million) Series A financing to create new treatments for Alzheimerโs disease
October 9, 2023London UK, XXXXโ AstronauTx Ltd. (โAstronauTxโ), a biotech company developing novel treatments for Alzheimerโs disease and other neurodegenerative disorders today…UK biotech group raises ยฃ48mn for Alzheimerโs research
October 8, 2023AstronauTxโs financing is step towards helping millions of people suffering from disease View the articleยFierce Biotech Names Cerevance a โFierce 15โ Biotech Company of 2023
August 28, 2023Boston, MA โ August 28, 2023 โ Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision…A born listener: CNS startup Violet hones in on cellular cross-talk
July 25, 2023The identification of new targets in diseases of the central nervous system (CNS) such as Alzheimerโs and Parkinsonโs โ conditions…DDF: Unleashing innovation, a new era for dementia
July 6, 2023Dementia, the looming health crisis of our time, has long lacked effective treatments. But now, recent drug breakthroughs and the…Renowned Neuroscientist Prof. Michael Heneka, M.D, Joins The Dementia Discovery Fund (DDF) as Scientific Advisor
June 28, 2023Boston, MA (US) and London (UK) โJune 28th 2023. The Dementia Discovery Fund (DDF), the worldโs largest family of specialized venture capital…Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer’s Dementia Validation Trial
May 31, 2023Oxford and Cambridge Among Sites Participating in CNS-101 Validation Study BELFAST, Northern Ireland and CAMBRIDGE, Mass., May 31, 2023 /PRNewswire/…Violet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV)
May 31, 2023Round led by the DDF (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and founding investor…First Steps to Treating Dementia May Lie in Related Diseases
May 19, 2023AARP-backed research into ALS, Alzheimerโs could lead to dementia drugs View the articleTherini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimerโs Disease
May 15, 2023SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Therini Bio, Inc., a biotech company focused on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and…Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
April 27, 2023Funding from top-tier syndicate will be used to advance potential first-in-class investigational antibody THN391 into clinical trials. SOUTH SAN FRANCISCO,…Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting
April 18, 2023BRISBANE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build…QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
April 6, 2023First patient dosed in Canada in Phase 1 ANQUR study โ the first-ever clinical trial to evaluate a therapy that…ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
March 9, 2023QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA…QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
March 9, 2023EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round Financing supports clinical activities for Companyโs two lead programs…AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology
February 23, 2023โข Subpial delivery technology has the potential to offer precise, efficient, and safer delivery of gene therapies for neurological diseases with…Impact funds help fight dementia and antibiotic resistance
February 20, 2023Some of the worldโs biggest health challenges do not lend themselves to conventional investment โDementia is a massive, massive swing…Cerevance Expands Series B Financing with Additional $51 Million
February 13, 2023Proceeds will advance Cerevanceโs potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinsonโs disease will advance to Phase…QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
January 5, 2023QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration CAMBRIDGE, Mass., January 5, 2023 โ QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision…Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases
December 13, 2022Cambridge, UK โ December 13, 2022 โ Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today…QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
December 8, 2022First ever study to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients expected to initiate in Canada in…Nitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium
October 31, 2022Company discovered selective nitration and regulation of tumor-intrinsic and immuno-oncology targets by several of its proprietary nitrases BRISBANE, Calif., Oct.…DDF recognizes that the latest lecanemab results represent major progress in the development of new treatments for Alzheimerโs disease.
September 29, 2022Eisai and Biogen report positive results from lecanemab Phase 3 study in Alzheimerโs disease with a statistically significant slowdown in…Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer
September 21, 2022Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital…AviadoBio selected by Fierce Biotech as a โFierce 15โ 2022 winner
September 12, 2022โข Award reinforces AviadoBioโs position as one of the most promising early-stage biotech companies in the gene therapy industry London,…Alchemab Therapeuticsโ Cracking the secrets of protective auto-immunity
September 12, 2022Searching for protective antibodies in โresilientโ people may provide a new approach for discovering drug targets. View the articleNitrase Therapeutics Appoints Arun Kashyap, Ph.D., to Lead its Recently Launched Oncology Programs as Senior Vice President of Oncology
September 7, 2022BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build…On heels of Parkinsonโs readout, Cerevance enters Alzheimerโs discovery deal with Merck
August 9, 2022Pharma pays $25M up front to use target discovery platform as privately-held Cerevance plots path forward for wholly-owned clinical program…Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimerโs Disease
August 9, 2022Cerevance to concurrently out-license one discovery-stage program Boston, MA โ AUGUST 9, 2022 โ Cerevance, a private, clinical-stage drug discovery and…Nitrase Therapeutics Expands Leadership Team with Accomplished Drug Discovery and Development Executives
July 6, 2022SAN FRANCISCO, July 06, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its unique NITROME platform to…QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board
June 21, 2022Industry veteran brings proven track record in building successful businesses and leading high-performance teams across large pharmaceutical, biotech, and specialty…Transine Therapeutics Announces Final Closing of its Seed Round at ยฃ13.7m to Accelerate its Platform and Portfolio Development
May 31, 2022Cambridge, UK, 31 May 2022: Transine Therapeutics (โTransineโ), a biotechnology company developing a novel class of therapeutic RNAs based on…AviadoBioโs Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia
April 27, 2022โข FDA and EC decisions reinforce severity of unmet medical need with this rare, aggressive form of dementia โข AviadoBio…Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
April 19, 2022Craig Thompson Appointed Chief Executive Officer Founder Brad Margus Assumes Role of Executive Chairman of the Board Boston, MA โ April…Nitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinsonโs Research
April 5, 2022-- Grant to fund exploration of potential new biomarker for Parkinsonโs disease -- BRISBANE, Calif., April 05, 2022 (GLOBE NEWSWIRE)…Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinsonโs Disease Drug Working Through a New Mechanism
March 31, 2022Demonstrates the Power of Cerevanceโs Deep Understanding of Specific Human Brain Cell Types Boston, MA โ March 31, 2022 โ Cerevance,…Fast-track dementia to curb it like Covid
March 20, 2022The coronavirus gave us a blueprint for tackling a health crisis: cut red tape and fund more research โ but…LoQus23: going upstream to slow Huntingtonโs disease
March 19, 2022By targeting the DNA damage repair pathway, the U.K. biotech hopes to stop the formation of mutated HTT, not clean…Nitrase Therapeutics Announces Major Discovery In Parkinsonโs Disease Presented At The AD/PD International Conference
March 18, 2022-Company Identifies Potential New Biomarker And Diagnostic For Parkinsonโs Disease- SAN FRANCISCO, March 18, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc.…Caraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD
March 2, 2022โ Esteemed Harvard Medical School Professor Emeritus and HHMI Investigator, Dr. David Clapham, brings world class expertise on ciliary ion…LoQus23 Therapeutics appoints Dr. Melanie Ivarsson, OBE, as Non-Executive Director
January 25, 2022Dr. Ivarsson is currently Chief Development Officer at Moderna and led clinical trials of the companyโs Covid-19 vaccineCambridge, UK โ…AviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
December 1, 2021London, UK, December 2, 2021 โ AviadoBio Ltd, a pioneering gene therapy company focused on developing and delivering transformative medicines…LoQus23 Therapeutics exits stealth with ยฃ11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
November 23, 2021- Company targets DNA mismatch repair pathways to slow neurodegeneration in Huntington's Disease and other triplet repeat disorders - LoQus23's…Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series A to $45M, and Changes Company Name to Nitrase Therapeutics
November 2, 2021--Founder Irene Griswold-Prenner, Ph.D., Focuses on Role as Chief Scientific OfficerโSan Francisco, CA โ November 2, 2021ย โ Nitrase Therapeutics, Inc.…Why Bill Gates is optimistic about the future of Alzheimerโs research
September 22, 2021If we want to stop Alzheimerโs disease, one of the biggest things we need to develop is a reliable, affordable,…QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2
September 14, 2021QRL-201 is a first-in-class molecule that rescues STATHMIN-2 loss of function in motor neuron disease models in the presence of…Cumulus Neuroscience Appoints Dr Ruth McKernan CBE as Chair
September 14, 2021BELFAST, Northern Ireland, Sept. 14, 2021 /PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical…Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO
July 5, 2021Dr Thirkettle is a seasoned life sciences executive with deep experience and a proven track record in building successful novel…GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
July 2, 2021GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation of…AARP celebrates DDF’s three-year anniversary of the final close of the Fund
June 24, 2021Three years later, Dementia Discovery Fund now backs 18 companies seeking treatments View the articleAlchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer
June 22, 2021Industry Veteran Brings Experience and Proven Track Record of Success Plans for Management Team Expansion and Global Reach Through Newly…Kate Bingham is recognised in this year’s Queenโs Birthday Honours List
June 12, 2021We are delighted to share the news thatย Kate Bingham, Managing Partner in the SV Biotech team, has been recognised in…Right or wrong, the aducanumab decision could turbo-boost investor interest in neurodegeneration
June 11, 2021Biocentury articleThe Dementia Discovery Fundโs Portfolio Company Caraway Therapeutics Establishes Collaboration with AbbVie to develop small molecule therapeutics targeting Parkinsonโs disease and other neurodegenerative disorders
June 9, 2021Boston, MA (US) and London (UK) โ June 9, 2021. The Dementia Discovery Fund (DDF) is pleased to announce that Caraway Therapeutics,…Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinsonโs Disease and Other Related Disorders
June 9, 2021CAMBRIDGE, MA โ June 9, 2021 โ Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to…The Dementia Discovery Fund welcomes FDAโs approval of aducanumab for Alzheimerโs disease
June 7, 2021Boston, MA (US) and London (UK) โ June 7th, 2021. The Dementia Discovery Fund (DDF), the venture capital fund investing in,…Transine Therapeutics Closes Extended Seed Funding of ยฃ9.1 million co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to advance its novel class of therapeutic RNAs
June 2, 2021New Company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression Cambridge, UK, 2nd June 2021: Transine Therapeutics…QurAlis Boosts World-Class Leadership Team With Addition of Three New Members
May 26, 2021Vikas Sharma, Ph.D., Shirley Lasch, and Tim OโBrien join team dedicated to developing new treatments for ALS and other genetically…Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
May 10, 2021Strengthens investor syndicate with SV's Impact Medicine Fund, MRL Ventures and Sanofi Ventures joining to accelerate development of disease-modifying drugs…The Dementia Discovery Fund Appoints Luca Santarelli, M.D., a Proven Neuroscience Leader, as the New Chair of its Scientific Advisory Board
May 5, 2021Boston, MA (US) and Londonย (UK) โ May 5th, 2021.ย The Dementia Discovery Fund (DDF), the venture capital fund investing in, and…Cumulus Neuroscience Announces ยฃ6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund
May 4, 2021Belfast, UK - 4 May 2021. Cumulus Neuroscience (Cumulus, The Company), formerly known as BrainWaveBank, announces a ยฃ6m financing round led…Alchemab raises ยฃ60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
April 15, 2021Funding round led by RA Capital Management with Lightstone Ventures and DHVC follows a Seed round led by SV Health…The Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio
April 7, 2021World-recognized experts Dr. Lynne Hughes and Dr. James Summers appointed as Venture Partners Boston, MA (US) and London (UK) โ April…Amathus Therapeutics signs strategic collaboration with Merck to Develop Treatments for Neurodegenerative Diseases
March 17, 2021Cambridge, MA, 17, March 2021 Amathus Therapeutics announced today a strategic collaboration with Merck, known as MSD outside the United…Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntingtonโs disease
March 16, 2021March 16, 2021 05:00 AM Eastern Daylight Time LONDON--(BUSINESS WIRE)--Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat…QurAlis Continues to Expand Leadership Team with Two Key Hires
February 2, 2021CAMBRIDGE, Mass., February 2, 2021โ QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS)…Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
January 6, 2021January 06, 2021 06:30 AM Eastern Standard Time DURHAM, N.C.--(BUSINESS WIRE)--Ribometrix, Inc., today announced a strategic collaboration with Genentech, a…Caraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinsonโs Disease
November 18, 2020CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company has been awarded a second research grant from The Michael J. Fox…Cerevanceโs CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
November 16, 2020Positive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia Boston, MA โ…Nitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson
November 12, 2020Nitrome SAB composed of esteemed experts and key scientific thought leaders in neurobiology and drug development SAN FRANCISCO, Nov. 12,…QurAlis named as one of Fierce Biotech’s 2020 Fierce 15
September 28, 2020According to Fierce Biotech, what makes QurAlis fierce:ย There are currently four drugs approved by the U.S. FDA to treat ALS:…Excellent news today from our portfolio company @Cerevance on the expansion of its Series B financing round, adding a further $20 million to the $45 million announced in April.
July 22, 2020The additional proceeds will aid in the development of the companyโs NETSseq platform which it is using to discover entirely…QurAlis Announces Agreement to Strengthen ALS Pipeline
July 1, 2020QurAlis to in-license lead excitotoxicity targeted ALS therapeutic candidates from LillyCambridge, MA, July 01, 2020ย โย QurAlis Corporation, a biotech company focused…AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer’s Disease
June 2, 2020MANCHESTER, England, June 2, 2020 /PRNewswire/ -- The therapeutics biotech AstronauTx announces a partnership with Concept Life Sciences, Contract Research…QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)
May 13, 2020Funding led by Polaris Partners, Mission BioCapital, INKEF Capital and the Dementia Discovery FundCAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a biotech company…Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases
April 23, 2020Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related DiseasesThe…Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer – an industry veteran who brings deep experience in drug development from leadership roles at Regeneron and Vertex
April 15, 2020CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new…Cerevance Closes $45 Million Series B Financing – proceeds to fund a diverse pipeline of therapeutics acting on novel targets for brain diseases
April 14, 2020BOSTON, MA, April 14, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases,…Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors
March 24, 2020March 23, 2020 at 8:30 AM EDTSOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC)…DDF notes the appointment of Christian Jung, PhD as Partner
September 9, 2019SV Health Investors announces the appointment of Christian Jung, PhD as Partner in the Dementia Discovery Fund Former Principal at…DDF notes AstronauTx secures ยฃ6.5 million Financing with Investment from DDF
August 12, 2019Press Release: August 12, 2019 AstronauTx secures ยฃ6.5 million investment for new approach to dementia therapeutics A new UK-based biotech…DDF launches new research accelerator partnership with the UK DRI
October 23, 2018Dementia Discovery Fund launches new research accelerator partnership with the UK Dementia Research Institute at inaugural Annual Forum for Dementia…Bill Gates announces new investment in Alzheimerโs research to help launch Diagnostics Accelerator
July 19, 2018The Dementia Discovery Fund welcomes Bill Gatesโ second investment in Alzheimerโs research. Bill is joining Leonard Lauder, ADDF, the Dolby…Dementia Discovery Fund Announces the Appointment of Angus Grant PhD as CEO
June 25, 2018Dementia Discovery Fund announces the appointment of Angus Grant PhD as CEODr Grant from Celgene to join DDF in JulyDementia…The Dementia Discovery Fund Raises $350 Million
June 25, 2018Includes $60 million new investment from US AARPThe DDF is the worldโs largest venture fund focused on a single disease…DDF Announce Research Collaboration with Immuneering
June 19, 2018The Dementia Discovery Fund and Immuneering announce a Research Collaboration to identify novel drug targets and drug candidates for Alzheimer's…DDF welcomes recent FDA guidance which opens new paths for Alzheimerโs treatments
February 20, 201813 February 2018The DDF welcomes new draft guidance from the FDA that endorses a new approach in Alzheimerโs Disease research…JLABS – Meet With…Dementia Discovery Fund
January 2, 2018Following last yearโs meetings in New York and Cambridge, the DDF are again pleased to be presenting at upcoming Johnson…DDF attracts investment from NFL Players Association
November 16, 2017London, 16 November 2017 - The Dementia Discovery Fund (DDF) today announces an investment from the US National Football League Players…DDF Invests in $20 Million in Series A Funding of Mitoconix Bio to Develop Neurodegenerative Disease Therapies
July 6, 2017Ness Ziona, Israel June 27, 2017 -ย Mitoconix Bio Ltd., a biopharmaceutical company focused on therapies for neurological diseases, announced today…Dementia Discovery Fund Annual Update
June 19, 2017Dementia Discovery Fund Annual Update Nine investments made since launch, collaborations established with world-leading academic institutions, scientific strategy prioritised and…Bicycle Therapeutics Closes ยฃ40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline
June 1, 2017CAMBRIDGE, England & CAMBRIDGE, MA. (June 1, 2017) โย Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based…DDF to Invest $5 Million in Cerevance to Seek New Treatments for Dementia
May 3, 2017Dementia Discovery Fund to Invest $5 Million in Cerevance to Seek New Treatments for Dementia London and Boston, 3 May…Autifony Therapeutics obtains ยฃ1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia
March 15, 2017London, UK - 15th March 2017 - Autifony Therapeutics Limited (โAutifonyโ), which is pioneering the development of novel pharmaceutical treatments…DDF Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes
February 28, 2017LONDON, BOSTON, GREENWICH, 28 February 2017 โ The Dementia Discovery Fund (โDDFโ), a venture capital fund focused on discovering and…Launch of Dementia Discovery Fund New Fund Raises $100 Million to Deliver Novel Approaches to Treatment of Dementia
October 21, 2016London, 21 October 2015, The Dementia Discovery Fund (DDF), an innovative new global investment fund to support discovery and development…DDF invests in Gen2 Neuroscience Ltd
June 3, 2016Gen2 is a start-up drug discovery company seeking to develop drugs that target toxic tau species that cause pathology in…SV appoints world-renowned Chief Scientific Officer to lead the new DDF investment team
January 25, 2016London, 25 January 2016 - The Dementia Discovery Fund (DDF) www.TheDDFund.com, an innovative global investment fund launched in October 2015 to…DDF Makes First Investment In Alector LLC
January 7, 2016First investment of Dementia Discovery Fund is in pioneering immuno-modulatory antibody discovery company, Alector LLCAlector LLC is developing antibody drugs…